Jyong Biotech
MENS
8 hedge funds and large institutions have $4.15M invested in Jyong Biotech in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
431% more capital invested
Capital invested by funds: $781K → $4.15M (+$3.37M)
300% more funds holding
Funds holding: 2 → 8 (+6)
0.02% more ownership
Funds ownership: 0.12% → 0.14% (+0.02%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.94M |
| 2 |
Millennium Management
New York
|
+$468K |
| 3 |
Morgan Stanley
New York
|
+$103K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$61.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.1M |
| 2 |
HF
HRT Financial
New York
|
-$75.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $2.12M | +$1.94M | +53,844 | New |
|
|
HF
2
HRT Financial
New York
| $819K | -$75.7K | -2,103 | -9% |
|
|
3
Millennium Management
New York
| $512K | +$468K | +13,013 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $498K | -$2.1M | -58,329 | -82% |
|
|
5
Morgan Stanley
New York
| $113K | +$103K | +2,871 | New |
|
|
6
BNP Paribas Financial Markets
Paris,
France
| $66.9K | +$61.1K | +1,698 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $21.1K | +$19.3K | +537 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1.02K | +$936 | +26 | New |
|
MENS Hedge Fund Activity: Q3 2025 in Review
8 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Jyong Biotech (MENS) for Q3 2025, worth a combined $4.15M — up 431% from $781K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MENS positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Citadel Advisors, cutting an estimated $2.1M.
- 8 institutional investors held Jyong Biotech (MENS) as of Q3 2025, up from 2 in Q2 2025.
- Funds reported $4.15M of Jyong Biotech stock for Q3 2025, up 431% quarter-over-quarter.
- 6 funds opened new Jyong Biotech positions in Q3 2025 and 0 closed out, a net change of +6 holders.
- The largest Jyong Biotech buyer in Q3 2025 was Geode Capital Management, an estimated $1.94M added.
- The largest Jyong Biotech seller in Q3 2025 was Citadel Advisors, an estimated $2.1M sold.
Based on aggregated 13F filings for Q3 2025.